Hydrofarm Holdings Group Q1 2024 Earnings Call Transcript

Quartr
Provided by Quartr
May 14, 2024

There are 7 speakers on the call.

Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Hydrofarm Holdings Group First Quarter 2024 Earnings Conference Call. At this time, all participants have been placed in a listen only mode and the lines will be open for your questions following the presentation. Please note that this conference is being recorded today, May 14, 2024. I would now like to turn the call over to Anna Kate Heller of ICR to begin.

Operator

Please go ahead.

Speaker 1

Thank you, and good morning. With me on the call today is Bill Toler, Hydrofarm's Chairman and Chief Executive Officer and John Lindeman, the company's Chief Financial Officer. By now, everyone should have access to our Q1 2024 earnings release and Form 8 ks issued this morning as well as an investor presentation available for reference. These documents are available on the Investors section of HydroPharm's website at www.hydrapharm.com. Before we begin our formal remarks, please note that our discussion today will include forward looking statements.

Speaker 1

These forward looking statements are not guarantees of future performance and therefore, you should not put undue reliance on them. These statements are also subject to numerous risks and uncertainties that could cause actual results to differ materially from our current expectations. We refer all of you to our recent SEC filings for a more detailed discussion of the risks that could impact our future operating results and financial condition. Lastly, during today's call, we will discuss non GAAP measures, which we believe can be useful in evaluating our performance. The presentation of this additional information should not be considered in isolation or as a substitute for results prepared in accordance with GAAP and reconciliations to comparable GAAP measures are available in our earnings release.

Speaker 1

With that, I would like to turn the call over to Bill Toler.

Speaker 2

Thank you, Anne and Kate, and good morning, everyone. I am pleased to report that in our Q1, we delivered better results in many key profitability metrics, including adjusted gross profit margin, adjusted EBITDA, adjusted EBITDA margin and free cash flow. In addition, March 2024 marked the 5th consecutive month of sequential net sales growth for HydroPharm. That's the longest string of sequential monthly growth we have seen since our IPO in 2020. 2nd, we have now increased our adjusted gross profit margin on a year over year basis across the last 5 consecutive quarters, And we achieved adjusted positive positive adjusted EBITDA in 3 of the past 4 quarters, demonstrating our ability to continue to operate profitably during industry downturn.

Speaker 2

While we are far from satisfied with the $2,700,000 of positive adjusted EBITDA that we have reported over the last 12 months, it is clear that our cost savings and restructuring actions are making a difference. And when sales begin to increase, this volume will make an even larger impact on our bottom line. Our biggest opportunity is to continue to find new and unique ways to drive profitable growth. To accomplish that, we are innovating and expanding our brands to address growers' needs. For example, at the end of Q1, we launched a new and improved photobiode light designed specifically for commercial growing applications that offers 10% more light output, 47% less weight in the fixture and increased efficacy, all at a 20% lower price than comparable models.

Speaker 2

While we are still in the early innings of this product innovation, we did see year on year growth on the Fotobio brand in Q1. 2nd, we continue to diversify our revenue stream by driving sales in our non cannabis markets and broadening our geographic reach. In Q1, our non cannabis and non North American revenue sources increased to an estimated 32% of sales, representing approximately a 360 basis point increase from the prior year. In addition to our diversification strategies, the regulatory environment is finally getting better for U. S.

Speaker 2

Cannabis growers. It's improving and will help drive sales in the industry in the future. Recently, we all read the DEA will propose the reclassification of marijuana from a Schedule 1 to a Schedule 3 drug, a significant step in the process to legalize cannabis in the U. S. Separately, in April, we learned that the Florida Supreme Court will allow the state's voters to decide on the November ballot whether to legalize adult use marijuana or not in the State of Florida.

Speaker 2

These are good signs for our industry. While the financial metrics we just reported are central to this earnings call, I want to share a broader view of what I believe to be the beginning of a turn in the industry. I mentioned the 5 consecutive months of sequential sales growth, that's encouraging, but we're also seeing recent stabilization in our core U. S. Business.

Speaker 2

Some of this is driven by innovation like the previously mentioned photo value LED lights and some of it simply that supply and demand are rebalancing across the country. Proprietary brands including Growtech, Roots Organic, Gaia Green and Photo Bio grew in Q1 compared to the prior year. Couple the slight improvement in demand with our tight control and costs, including our adjusted SG and A being 24% lower in Q1 this year versus last, and we are well positioned for continued improvement in profitability as volume returns. We are reaffirming our full year guidance for net sales, adjusted EBITDA and free cash flow as we remain focused on our brands, diversification of revenue and improved mix in controlling and reducing costs. With that, I'll turn it over to John to further discuss the details of Q1 and our outlook for 2024.

Speaker 3

John? Thanks,

Speaker 4

Bill, and good morning, everyone. Net sales for the Q1 were $54,200,000 down 12.9% year over year, driven primarily by a 12.6% decrease in volumemix. The decrease in volumemix was mainly related to oversupply in the cannabis industry. Additionally, pricing was relatively flat in Q1 as we lap price concessions made in the Q1 of 2023. In the Q1, consumable products represented approximately 76% of our sales compared to 72% in the Q1 of 2023.

Speaker 4

This higher mix of consumables was led by a year over year sales increase in Grow Media Products, including our own proprietary Roots Organics and Gaia Green Brands. During the quarter, we maintained a strong mix of proprietary brands at approximately 57% of our total net sales relatively consistent to the same period last year. Gross profit in the Q1 was $10,900,000 compared to $11,400,000 in the year ago period. Adjusted gross profit was $12,700,000 or 23.4 percent of net sales compared to 14.1 percent or 22.6 percent of net sales. This 80 basis point increase is primarily the result of improved productivity inside our manufacturing plants.

Speaker 4

This marked our 5th consecutive quarter of year over year adjusted gross margin expansion. And while we are pleased with our progress, we do feel there's some opportunity to further improve upon this metric as we track across the remainder of 2024. Now a quick update on our restructuring plan. As we previously mentioned, our 2nd phase of restructuring was largely focused on rightsizing our manufacturing footprint, particularly with respect to durable equipment products. We announced today the signing of an agreement in which we are selling the manufacturing equipment and on-site inventory related to our IGE branded products for approximately $8,700,000 in cash.

Speaker 4

As part of the transaction, we will no longer be responsible for carrying the heavy manufacturing labor and overhead costs or the investment in costly steel aluminum necessary to build our high quality IGE products. Instead post transaction, our new exclusive co manufacturer will produce our IGE products, helping us to variabilize our cost structure and ultimately improve our profit margin profile on this product set. We are excited about the prospects for both HydroPharm and our new exclusive co manufacturer with whom we expect to enjoy a close relationship going forward. We expect the transaction to close in the Q2. Now let me move on to our selling, general and administrative expense, which we dramatically reduced from the prior year period.

Speaker 4

In the Q1, our SG and A expense was $19,600,000 compared to $24,400,000 Adjusted SG and A expenses were $12,300,000 nearly a 24% reduction when compared to $16,200,000 in the Q1 of 2023. This was primarily due to a reduction in facility expenses, professional fees, insurance costs and headcount. It is worth noting that much of this reduction is due to the cost we took out as part of our restructuring actions in the first half of twenty twenty three. Adjusted EBITDA was $300,000 in the first quarter compared to a loss of $2,100,000 in the prior year period. The $2,400,000 improvement and the 400 basis point expansion in adjusted EBITDA margin was driven by our improved adjusted gross profit margins and our reduced adjusted SG and A expenses.

Speaker 4

We continue to demonstrate our ability to generate positive adjusted EBITDA, which is a testament to the effectiveness of our restructuring and cost saving initiatives along with our focus on proprietary brand sales mix. Moving on to our balance sheet and overall liquidity position. Our cash balance as of March 31, 2024 was 24,200,000 We ended the Q1 with $120,500,000 of term debt and approximately $130,000,000 of total debt inclusive of finance lease liabilities. Our net debt at the end of the quarter was approximately 106,000,000 dollars As a reminder, our term loan facility has no financial maintenance covenant and does not mature until October 2028. We continue to maintain a zero balance on our revolving credit facility and at this point we have not borrowed against our revolver for 9 straight quarters.

Speaker 4

In the Q1, we reported cash used in operating activities of $2,300,000 with capital expenses of 1,400,000 dollars yielding negative free cash flow of $3,700,000 I will remind you that the Q1 is a seasonally low period for our free cash flow and we achieved a significant nearly $7,000,000 improvement from the prior year period, which we accomplished through positive adjusted EBITDA and disciplined reduction of inventories and working capital levels. We remain on track to deliver our positive free cash flow guidance for the full year. With that, let me turn to our full year 2024 outlook. We are reaffirming our 2024 guidance, which includes net sales to decline low to high teens on a percentage basis, adjusted EBITDA that is positive for the full year 2024 and lastly, positive free cash flow for the full year, which includes the continued expectation of $4,000,000 to $5,000,000 of capital expenditures. To wrap up, we remain on the right path and we'll continue to control what we can.

Speaker 4

We are operating profitably despite lower sales levels. Our restructuring plan and cost saving initiatives have proven effective. And as Bill discussed before, there are reasons for optimism on the demand side of our industry as we look ahead. We are excited about the future of this business and we look forward to continued improvement throughout the year. Thank you all for joining us.

Speaker 4

We're now happy to answer your questions. Operator, please open the line.

Operator

Thank you. Ladies and gentlemen, we will now be conducting a question and answer Our first question is from the line of Peter Grom with UBS. Please go ahead.

Speaker 3

Thanks, operator. Good morning, everyone. Hope you're doing well. Maybe just a couple of quick ones from me. Just first on the guidance from the revenue perspective.

Speaker 3

Maybe personal, can you maybe just remind us, I might have misheard you, but you talked about some monthly improvements, some of the best you've seen since the IPO. So maybe just can you just repeat that for us? And then taking a bigger picture and looking at kind of the reported numbers here, you've had some sequential improvement in sales trends over the last 5 quarters or so. You started the year kind of at the better end of your top line guidance range. Can you maybe just help us understand what you're seeing from a top line progression or what you expect from a top line progression from here?

Speaker 3

Is there a reason that it could potentially step back from kind of this low double digit decline we saw? Or should we expect sequential continued improvement? And I guess within that, are you simply just kind of keeping this range to kind of be cautious given we're still very early in the year?

Speaker 2

No. Thanks, Peter, and good question. So the first one for clarification. We've seen sequential improvements in revenue, really from last October through March. So each month it's stepped up just a bit, October through March.

Speaker 2

So that's 5 consecutive months there. And that's the longest string of those since our IPO back in the end of 2020, which of course you remember. So on that, now the other question is around kind of guidance and we sort of are at the better end of the range now, why not move it up there and what can we expect to see, I think is where you're headed with that one. We are being conservative here. It is early in the year.

Speaker 2

We think things are looking pretty good, but we also had a very large quarter last Q2. So we're lapping up against some big numbers there and we just don't want to get ahead of ourselves. We've got such an important period here in really May, June, July going through the kind of the core of the outdoor season in late spring, early summer stuff. We just really don't want to get ahead of ourselves and try and take up numbers too quickly. We want to see that traction going on for a few more months and other things, but we are encouraged by recent trends.

Speaker 2

We're not overly giddy or optimistic yet, but we do think that things are certainly firming up as you probably heard from some others. And we're seeing some overall sales trends that finished up Q1 and then even starting Q2 that are encouraging for us as we go forward. But much like you suggested, it is early in the year. We don't want to get ahead of ourselves.

Speaker 3

Okay. That's helpful. And then I guess just on the asset sale announced this morning, can you maybe just remind us how big IG is as part of your kind of revenue mix? And when you talk about kind of the margin improvement as a result of this transaction, is there anything you can kind of in terms of the magnitude of improvement? I'm just trying to understand how much this could really move the needle here.

Speaker 3

Thanks.

Speaker 4

Yes, sure, Peter. I can jump in on that one. I mean, just in terms of magnitude, today as it sits, our IgE products are less than 10% of our total sales, somewhere closer to even almost a 5% than 10%. The magnitude is not that dramatic, but we did this because we do think it's a step that can continue to improve profit margin on those particular products. As you'll recall in the second half of last year, we did reduce and restructure that facility, the manufacturing facility outside Chicago.

Speaker 4

We took it down from like roughly 300,000 square feet to 200,000 square feet. We right sized the staff and made some other improvements in the business. But even in spite of those changes, we're still not getting at the kind of volumes we have today, we're still not getting the profitability we think we should on that business. So this step really rectifies that and the benefits should show through in the back half of this year.

Speaker 3

Great. Thanks so much. Best of luck. I'll pass it on. Thanks, Peter.

Operator

Thank you. Our next question is from the line of Andrew Carter with Stifel. Please go ahead.

Speaker 5

Hey, thank you. Good morning. I guess, the first thing I wanted to ask is kind of within the sale of IG, I know that last quarter there was kind of a message either shrink to profitability or grow. I guess have you picked a firm path? Does IGE signal that exactly?

Speaker 5

And has kind of the landscaping or you're thinking about the world changed following Hawthorne's announcement to partner with BFG?

Speaker 2

No, not really. I think IGE is a step that, as John mentioned, kind of assures more better profitability from that smaller business, positions us really more cleanly now as a manufacturer of brands in the consumable space and really gets us out of that durable piece. IGE was the only durable piece we had. It's not an area where we spend a lot of time or have a lot of synergy on. So we don't we didn't think being there was a good fit.

Speaker 2

And also the previous owner who we sold the assets back to and it's important to recognize we didn't sell the business back to him. We still own the brand. We still have the business. So this should have little to no effect on our revenue through IGE IGE in terms of either getting smaller or getting bigger. This is really just kind of a tactical step to clean up the portfolio and make us more focused on the consumables where we're now doing 75% of our business in total or so.

Speaker 2

So we still are looking for options to expand our footprint and to get kind of what I would call that hydro farm 2.0, which we're not there yet. So ideas out there include different kinds of combinations, different kinds of ideas. So we're still working on that and know that that is an important step for us to be ready for the industry, which does feel like it's starting to strengthen a bit.

Speaker 5

Got it. And then I guess the second question is the pricing looked pretty decent at least compared to what Hawthorne reported and then kind of GrowGen implied. In terms of kind of the promotional activity out there, would you say where would you say that is right now? Are you foregoing into business? And I guess within that minus 12.6 volume mix decline, was there any portion of that that was purposeful trading out more profitable volume versus lower?

Speaker 5

I know that there was proprietary outperform, but

Speaker 1

I'll just stop there. Thanks.

Speaker 4

Yes. No, I don't think the 12.6 percent, a lot of it was intentional. I mean, I think it's just sort of continued conditions that we see in the industry. The good news there is obviously those declines have been improving as we've been marching across the calendar here the last 18 months. It's a good news there.

Speaker 4

And then the pricing being relatively flat, Andrew, which you called out really relates to price concessions

Speaker 5

we made in the Q1

Speaker 4

last year and a little bit into the second which we were really pushing to sell through during that period of time. So hopefully that all fits for you.

Speaker 5

It does. Thanks. I'll pass it on.

Speaker 2

Thanks, Andrew.

Operator

Thank you. Our next question is from the line of Jesse Redmond with Water Tower Research. Please go ahead.

Speaker 6

Good morning, guys. Congratulations on the quarter. I had a question about the improving macro I had a question about the improving macro environment that you referenced. One of the big things going on is potentially finally seeing some political progress. Although you're not explicitly impacted by 280E removal, can you talk about how Schedule 3 may benefit your business and if you expect to see the purse strings loosening at some of the bigger MSOs as they start to get more cash flow?

Speaker 2

Yes, I think that there are numbers out there that say there could be up to a couple of $1,000,000,000 that used to be paid in taxes that now can be reinvested back in the industry. And obviously, that's kind of good news for everybody, right? And we all can even go out and fight for our share of that. So that's the impact that we expect, which is terrific. But the reality is this is still a long process, right?

Speaker 2

It's still now been recommended, then there's going to be hearings and there's going to be this, there's going to be that. All this stuff is going to take time. And I think that it's important to recognize that we're focused on operating today and finding the right solution for our company today. And all those things will happen down the road, we believe. But we're not sitting around waiting for the government to solve our problems or the government to fix our business.

Speaker 2

We're making sure that we're operating profitably and figuring out the right long term solution for Hydrofarm as these things get implemented over the next, let's call it, 6, 12, 18, 24 months.

Speaker 6

And my second question is at the state level. We obviously have some good opportunities ahead of us with potentially Florida and maybe Pennsylvania. But this summer, we have Ohio rolling out, which is happening more quickly and in a manner that looks like it should be a pretty good market for most operators. Can you talk a little bit about Ohio and what that market potentially represents for you?

Speaker 2

Yes. Ohio has started to show some vibrance and we're growing very nicely on a small base in Ohio just as we are in Florida and some of the other rollout states like Missouri and other place. So we are seeing that start to pick into the industry, which is really encouraging. The other thing we're seeing across the pond, if you will, is with Germany passing 90,000,000 people that are very cannabis friendly and it's a highly consumed product in Germany. We are well positioned over there with all of our brands we've rolled out.

Speaker 2

We had a business in Spain that's positioned across all of Europe for a number of years. So we are moving resources and people and assets into Germany to be ready to take advantage of that. And importantly, the way that Germany laws work, it's going to be a very favorable home market. It's not going to be driven by LPs or MSOs or large entities. It's going to be driven much more by the at home grower, which is a terrific thing for a company like ours and brands that people can use at home and know and trust.

Speaker 2

And so we think that while there's some states that are popping here in the U. S. Are showing some nice vibrance, We also think that the Germany opportunity really opens us up to call it another 100,000,000 consumers, if you will, of people that are very cannabis friendly and a culture that we think is going to be right for us to grow in.

Speaker 6

Great. I appreciate the comments. Thank you.

Speaker 2

Thank you, Jesse.

Operator

Thank you. Ladies and gentlemen, as there are no further questions, I now hand the conference over to Bill Toler for his closing comments. Bill?

Speaker 2

Thank you, Ryan, and thank you everyone for supporting and following Hydrofarm. We look forward to further updates through the summer and hope everyone is doing well. Thanks so much.

Operator

Thank you. The conference of Hydrofarm Holdings Group has now concluded. Thank you for your participation. You may now disconnect your lines.

Powered by Quartr

Key Takeaways

  • Hydrofarm reported net sales of $54.2 million in Q1, down 12.9% year-over-year, but achieved positive adjusted EBITDA of $0.3 million versus a $2.1 million loss last year and marked the 5th consecutive month of sequential net sales growth.
  • The company expanded its adjusted gross profit margin by 80 basis points to 23.4%—its 5th straight quarter of year-over-year margin improvement—while cutting adjusted SG&A expenses by 24% through restructuring and cost-savings initiatives.
  • As part of its restructuring plan, Hydrofarm agreed to sell the manufacturing equipment and inventory for its IGE durable products for $8.7 million in cash, shifting to a co-manufacturing model to variabilize costs and enhance margin profile.
  • The company is driving growth through innovation and diversification, launching a new Photo Bio commercial LED light with 10% more output at 20% lower price and increasing non-cannabis and non-North American revenues to 32% of sales, up ~360 basis points.
  • Hydrofarm reaffirmed its full-year guidance of a low-to-high teen percentage decline in net sales alongside positive adjusted EBITDA and free cash flow, while citing industry stabilization, improving U.S. cannabis regulations, and new market opportunities like Germany’s home-grow segment.
A.I. generated. May contain errors.
Earnings Conference Call
Hydrofarm Holdings Group Q1 2024
00:00 / 00:00